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Abstract 
Nutritional supplements are widely taken by the general population and several of these products are marketed 
specifically to improve eye health. The aim of this review is to summarise the evidence for the benefit of 
supplementation with antioxidant vitamins and other micronutrients for three of the most common eye diseases 
of the elderly: age-related macular degeneration (AMD), cataract and dry eye syndrome (DES). Although the 
potential importance of diet and nutrition in these conditions is strongly supported by data from observational 
studies, evidence from randomised controlled trials (RCTs) on the benefit of nutritional supplementation is 
generally lacking. However, there is high quality evidence to support the use of an Age-Related Eye-Disease 
Study (AREDS) supplement containing antioxidants (-carotene, vitamin C and vitamin E) and zinc to slow 
progression in those at moderate to high risk of developing advanced AMD. Recent data from the AREDS2 trial 
provided data to suggest that -carotene could be replaced with lutein and zeaxanthin on the based on improved 
safety without compromising efficacy. Although there is currently insufficient evidence to recommend the 
routine use of any of the commercially available supplements in cataract and DES, given the public health 
importance of these conditions further research into the benefit of dietary modification or nutritional 
supplementation should be a priority. 
 
Introduction 
Based on data from large cross-sectional surveys, it has been estimated that up to two thirds of the adult 
population of the US regularly takes one or more nutritional supplements [1, 2]. These are most often 
combinations of vitamins and minerals, but products containing essential fatty acids (EFA) or other 
micronutrients are also commonly used. Nutritional supplement use tends to be more common among women 
than men and the likelihood of taking supplements generally increases with age [3]. The most frequently 
reported motivation for taking these products is to maintain or improve overall health and supplement users tend 
to be better educated and more likely to adopt healthy lifestyle behaviours than non-users [4]. Despite their 
widespread use, high quality evidence that vitamin and mineral supplements improve general health outcomes 
or prolong life is lacking and it is possible that high doses of certain micronutrients may be harmful [5]. 
Systematic reviews of randomised controlled trials (RCT) for primary prevention have shown that antioxidant 
supplements do not seem to prevent cancer, cardiovascular diseases, or death [6, 7]. A meta-analysis combined 
with trial sequential analysis of 53 trials with a low risk of bias found that supplements containing beta-carotene 
and vitamin E in doses higher than the recommended daily allowance  (RDA) were associated with a  significant 
increase in mortality [8]. It is important to note that most placebo controlled trials of supplements for primary 
and secondary prevention are conducted in industrialised countries in generally well-nourished populations. It is 
therefore not possible to rule out a benefit of supplementation in nutritionally compromised individuals. 
However, for the general population current evidence suggests that the case for vitamin supplementation to 
improve health outcomes is poor. In 2013, an Editorial in Annals of Internal Medicine [9] concluded:  
‘Although available evidence does not rule out small benefits or harms or large benefits or harms in a small 
subgroup of the population, we believe that the case is closed- supplementing the diet of well-nourished adults 
with (most) mineral or vitamin supplements has no clear benefit and might even be harmful. These vitamins 
should not be used for chronic disease prevention. Enough is enough.’ 
The potential value of specific combinations of micronutrients to improve eye health is frequently promoted by 
micronutrient manufacturers as ‘eye nutrients’ and approximately 4% of supplement usage is reported to be 
specifically for this purpose [4].  The well-publicised results of large National Eye Institute (NEI)-funded trials 
in the US (Age-Related Eye Disease Study (AREDS) and AREDS2), demonstrating the value of antioxidant 
supplements in reducing the risk of developing advanced age-related macular degeneration (AMD), may have 
further contributed to their widespread use and promotion in the elderly. Recent surveys of optometrists and 
ophthalmologists have revealed that nutritional supplementation is now part of routine clinical practice for 
patients with or at risk of AMD [10, 11] although these recommendations are frequently not evidence-based 
[10]. The aim of this mini-review is to consider evidence for the value of nutritional supplementation in three 
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common age-related eye diseases: AMD, cataract and dry eye. The article will summarise data from recently 
published systematic reviews on nutritional supplementation published by the Cochrane Eyes and Vision Group.  
 
Age-related macular degeneration 
Although in global terms, AMD ranks third as the leading causes of visual impairment [12], it is the most 
common cause of blindness in European-derived populations. For example in the UK, AMD is responsible for 
over 50% of blind and partially sighted registrations [13] and with an ageing population the prevalence of the 
disease is predicted to increase substantially [14]. In addition to the obvious personal impact of AMD, the 
societal burden is also considerable. Economic costs arise from both the direct costs of treatment as well as 
indirect costs associated with visual impairment, including the provision of social care [15].  Although 
treatments in the form of anti-vascular endothelial growth factor inhibitors are available that can slow the 
progression of the neovascular form of the disease (so called ‘wet’ AMD), there is still no effective treatment for 
atrophic (‘dry’) AMD, which affects over 90% of sufferers. It is likely that the pathogenesis of AMD is multi-
factorial, arising from the complex interplay between genetic and environmental factors [16]. Oxidative stress 
has been implicated as a causative factor in the development of AMD, since the action of light on retinal 
photoreceptors generates potentially damaging free radicals [17].  Although the presence of macular pigment is 
thought to limit cellular damage by absorbing incoming blue light and/or quenching free radicals, it has been 
proposed that AMD could occur due to the cumulative effects of oxidative damage on macular photoreceptors 
and the underlying retinal pigment epithelium (RPE) [17]. Consequently, increased consumption of antioxidants 
through the diet has attracted significant interest as a simple, widely applicable and cost-effective intervention. 
Observational studies have reported that dietary components such as antioxidant vitamins and certain 
carotenoids can reduce the risk of developing AMD or slow its progression (see [18] for a recent review). 
However, results from these non-experimental studies should be interpreted with caution, since people with a 
diet rich in particular nutrients may differ in other ways from those who do not. The highest quality evidence to 
assess the benefit of nutritional supplementation comes from randomised controlled trials (RCTs), where 
participants have been randomly allocated to receive either a dietary supplement or a placebo/no intervention. 
Evidence arising from such trials has been reviewed in two related Cochrane Systematic Reviews that were 
published in 2012 [19, 20] and a recently updated review in 2015 [21]. Two of these reviews focussed on the 
role of antioxidant vitamin and mineral supplements in the prevention [19] and progression [20] of AMD and 
one review investigated on the role of omega-3 fatty acid supplementation [21].  
The review on ‘antioxidant vitamin and mineral supplements for preventing age-related macular degeneration’ 
[19] included data from 4 trials, which provided high quality evidence that people aged 40 years and above in 
the general population are unlikely to prevent the development of AMD by taking supplements containing 
vitamin E (data from 3 trials) or -carotene (provitamin A) (2 trials). The included RCTs were large (enrolling 
between 1000 and 40 000 participants), conducted so as to avoid bias, and were consistent with each other. The 
pooled risk ratio (RR) for any antioxidant supplement in the prevention of any AMD was 0.98 (95% confidence 
interval 0.89 to 1.08) and for advanced AMD was 1.05 (95% CI 0.80 to 1.39). The review was unable to identify 
RCTs with respect to other antioxidant supplements, such as vitamin C, lutein and zeaxanthin, or any of the 
commonly marketed multivitamin combinations.  
The Cochrane review “Antioxidant vitamin and mineral supplements for slowing the progression of age-related 
macular degeneration” [20] included data from 13 trials, although these were generally small. Over half the 
participants were randomised in one trial (AREDS), which found a beneficial effect of antioxidant (-carotene, 
vitamin C and vitamin E) and zinc supplementation on progression to advanced AMD (adjusted odds ratio (OR) 
0.68, 95% CI 0.53 to 0.87) over an average of 6.3 years (Figure 1).  
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Figure 1. Cates plot illustrating the effect of antioxidant and mineral supplements in slowing the progression of 
AMD (data taken from [20]). In the control group approximately 30 people in 100 had progressed to advanced 
AMD over 6.3 years, compared to 24 (95% CI 20 to 28) out of 100 for the supplemented group. 
People taking supplements were also less likely to lose 15 or more letters of visual acuity on a standard EDTRS 
chart (adjusted OR 0.77, 95% CI 0.62 to 0.96). The other 12 trials included in the review were generally small 
with shorter follow-up periods (less than two years). No evidence for an effect of supplementation was seen in 
these smaller trials of shorter duration.  Since this review was written, the results of the AREDS2 trial have been 
published [22].  The rationale for this new study was the observational data that suggested that a high dietary 
intake of omega-3 fatty acids or increased consumption of the xanthophyll’s lutein and zeaxanthin were 
associated with a decreased risk of developing AMD [23].  Lutein and zeaxanthin are major constituents of the 
macular pigment and possess antioxidant and UV light filtering properties and so protect the photoreceptors and 
RPE from damage [24]. 
In AREDS2 participants took the original AREDS formulation (or a variation of thereof) as ‘standard care’ and 
were randomly assigned, using a factorial design, to additionally receive a placebo or a capsule containing 
lutein/zeaxanthin and/or omega-3 long chain polyunsaturated fatty acids (LCPUFA) . Patients were followed up 
for a median period of 5 years. The primary analysis found that the addition of lutein and zeaxanthin to the 
original supplement did not confer any additional benefit regarding progression to advanced AMD (hazard ratio 
(HR) 0.90, 98.7% CI 0.76 to 1.07) [22].  However, further exploratory analyses of the trial data, which 
compared those taking and not taking lutein/zeaxanthin suggested that lutein and zeaxanthin may be a more 
appropriate component of the AREDS formula than the -carotene in the original formula [25]. The secondary 
analyses of a direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.82 (95% CI, 
0.69-0.96; p =0.02) for development of any late AMD, 0.78 (95% CI, 0.64-0.94; p =0.01) for the development 
of neovascular AMD, and 0.94 (95% CI, 0.70-1.26; p =0.67) for development of central geographic atrophy. 
Eliminating -carotene could also be argued to be beneficial on safety grounds. The Alpha Tocopherol-Beta-
Carotene Cancer Prevention (ATBC) Study, which investigated the impact of supplemental -tocopherol and -
carotene on cancer incidence in male smokers, found that -carotene increased lung cancer incidence by 17% 
and overall mortality by 8%. [26]. Although the switch of carotenoids in the AREDS formula seems reasonable, 
it should be pointed that as with   -carotene 15 years ago, the long-term safety profile of this combination is 
unknown. Moreover, if lutein and zeaxanthin are the optimal carotenoids to be used, further work is required to 
determine the most effective dose [27]. 
AMD is a complex disease in which individual susceptibility is determined by a combination of genetic and 
environmental risk factors. There has been a significant interest in whether the beneficial effect of nutritional 
supplements is influenced by particular AMD genotypes [28-30]. Klein and co-workers provided some evidence 
for a treatment interaction in those AREDS participants with the complement factor H (CFH) genotype [28], 
which was specifically related to the zinc component of the formulation. A subsequent analysis of AREDS data 
similarly found that the response to supplementation was linked to specific genetic polymorphisms [29] and the 
study authors made the case for genotype-directed nutritional therapy. However, these findings could not be 
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confirmed in a recent retrospective analysis of a larger cohort of AREDS participants [30]. This study also 
highlighted serious methodological flaws in the sub-group analysis used in the previous study [29] and 
concluded that the AREDS supplement reduced the rate of progression of AMD across all genotype groups. 
  
There is a plausible biological rationale for supplementing with dietary omega-3 fats to prevent or slow the 
progression of AMD. The omega-3 fatty acid docosahexaenoic acid (DHA) accounts for 50% to 60% of the 
total fatty acid content of the outer segments of photoreceptors [31]. The constant turnover of outer segment 
membranes requires a continuous dietary supply of DHA or its precursors and a deficiency may therefore 
predispose to the development of AMD [31]. Further evidence comes from observational studies, which have 
reported that the consumption of fish or foods rich in omega-3 long-chain polyunsaturated fatty acids 
(LCPUFA) could reduce the risk of developing AMD [32-36]. Similarly, a nested cohort study within the Age-
Related Eye Disease Study (AREDS) found that participants at moderate to high risk of progressing to late 
AMD, who reported the highest consumption of omega-3 LCPUFA, were 30% less likely to develop advanced 
AMD when compared to those reporting the lowest consumption [37]. The recently updated Cochrane review 
‘Omega-3 fatty acids for preventing or slowing the progression of age-related macular degeneration’ [21] 
included two relevant RCTs [22, 38]. In one of the treatment arms of AREDS2 [22], subjects aged 50-85, at 
high risk of progressing to advanced AMD, were randomised to receive a daily dose of the omega-3 LCPUFA, 
DHA and eicosapentaenoic acid (EPA) or a control supplement. The median follow up period was 5 years. In 
the Nutritional AMD Treatment 2 (NAT-2) study [38], people aged 55-85 with neovascular AMD in one eye 
and intermediate AMD in the other were randomly assigned to receive a daily supplement containing DHA and 
EPA or a placebo for a period of 3 years. In both trials, the main outcome measures were the development of 
advanced AMD and progression to moderate or worse vision loss (defined as a loss of 15 or more letters on a 
standard EDTRS letter chart). The trials, which had a low risk of bias, provided high quality evidence that 
people taking omega-3 LCPUFA supplements were not at a decreased (or increased) risk of developing 
advanced AMD. The pooled HR for progression of AMD was 0.96, 95% CI 0.84 to 1.10 [21].  
In summary, the lack of an effective treatment for the majority of individuals with AMD represents a major 
public health problem. Most of the available evidence on diet and nutrition comes from cohort studies,where 
residual confounding from other lifestyle variables is always a problem. Such confounding can be avoided in 
RCTs, although such trials are expensive to conduct and are generally of short duration. The results of the 
landmark AREDS trial provided high quality evidence that people with AMD may experience a modest delay in 
progression of the disease by supplementation with a specific combination of antioxidants (vitamins C, E and -
carotene) and zinc. AREDS2 concluded that lutein/zeaxanthin may be a more appropriate than -carotene in 
AREDS-type supplements, given the valid safety concerns regarding this component. There are a number of 
unanswered questions; patients recruited into these trials were well nourished with an above average intake of 
dietary nutrients and it is not clear whether the results can be applied to the population as a whole. There is also 
limited data on the long-term safety of these supplements. In terms of primary prevention, there is currently no 
evidence that commonly marketed micronutrient formulations prevent the development of AMD. 
 
Cataract 
Cataract is defined as any visible opacity within the substance of the ocular lens and is further classified on the 
basis of its anatomical location:  cortical, nuclear or posterior sub-capsular [39]. Oxidative stress has been 
implicated in the pathogenesis of all cataract sub-types [39]. With advancing age, lens proteins become 
increasingly susceptibility to oxidative damage and post-translation modification leading to impaired visual 
acuity and a reduction in contrast sensitivity [39]. Age-related cataracts are the leading cause of blindness 
worldwide and are responsible for 51% of blindness in the population over 50, corresponding to approximately 
20 million people [12]. Supplementation with dietary antioxidants has been proposed as a strategy for cataract 
prevention and several observational studies have found an association between consumption of antioxidant 
vitamins or particular carotenoids and a reduced risk of cataract development (see [40] for a recent review). 
However, not all of these data are consistent and there is a risk that the reported outcomes may be subject to bias 
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and confounding. A Cochrane Systematic Review ‘Antioxidant vitamin supplementation for preventing and 
slowing the progression of age-related cataract’ was published in 2012 [41] and included data from 9 trials of 
generally high methodological quality, in which 117,272 individuals over the age of 35 had been randomised to 
receive antioxidant vitamins (-carotene, vitamin C and vitamin E, used alone or in combination) or placebo. In 
the pooled analysis, there was no evidence of effect for -carotene in reducing risk of cataract (2 trials) (RR 
0.99, 95% CI 0.91 to 1.08) or reducing rates of cataract extraction (3 trials) (RR 1.00 95% CI 0.91 to 1.10), 
vitamin E in reducing risk of cataract (3 trials) (RR 0.97, 95% CI 0.9 to 1.04) or cataract extraction (5 trials) 
(RR 0.98 95% CI 0.91to 1.04). Similarly, data from one RCT comparing vitamin C to placebo found no 
difference in rate of incident cataract (HR 0.97, 95% CI 0.85 to 1.12). The review authors concluded that ‘costs 
and adverse effects [of taking antioxidants to prevent cataracts] should be weighed carefully with unproven 
benefits before recommending their use’.  
Cataract outcomes were also included in the AREDS and AREDS2 trials. The original AREDS study reported 
that the use of a supplement containing antioxidant vitamins (-carotene, vitamin C, vitamin E) and zinc did not 
affect the development or progression of lens opacities over the trial period [42].  Similarly, AREDS2 found that 
the addition of lutein/zeaxanthin to the original AREDS formulation had no effect on the rates of cataract 
surgery or moderate vision loss [43].  
In summary, despite encouraging results from observational studies, RCTs that have evaluated the effect of 
particular antioxidant vitamins and carotenoids on the development of cataract or cataract extraction have failed 
to consistently establish a causal association or benefit. The lack of an effect of antioxidants in these relatively 
short-term trials could suggest that longer-term intake is required or that formulations containing multiple 
antioxidants are necessary to provide a clinically significant benefit.  Using the AREDS cohort and a Cox 
regression analysis of baseline factors that predicted cataract, the use of multivitamin supplements (Centrum, 
Wyeth Consumer Healthcare) was found to be associated with a lower risk of developing nuclear cataracts over 
an average of 9.8±2.4 years follow up [44]. This finding was consistent with the results of a RCT conducted in 
Italy [45] that was not included in the Cochrane review, although intriguingly in this study multivitamin use was 
associated with an increased risk of posterior sub-capsular cataracts. Cataract outcomes based on participant 
reports were also investigated in the multivitamin arm of the Physicians’ Health Study II (PHS II), a large-scale 
randomised trial of middle-aged and older men [46]. This study found that long-term daily multivitamin use was 
associated with a 9% lower risk of cataract compared to placebo (HR, 0.91; 95% CI, 0.83–0.99; p=0.04). Given 
the high prevalence of cataract in the elderly population [47], even a modest reduction in risk of cataract would 
potentially have a large public health impact, however potential benefits need to be balanced against the risk of 
harm. 
 
Dry Eye Syndrome 
Dry eye syndrome (DES) is one of the most common ophthalmic conditions in the world with an estimated 
prevalence of 5-30% of the population aged 50 and above [48]. DES occurs where the eye does not produce 
enough tears or where the tears evaporate too quickly. The condition is associated with inflammation of the 
ocular surface and leads to reduced ocular comfort, varying degrees of visual disturbance and a corresponding 
reduction in quality of life [49]. There has recently been a great deal of interest in the potential for oral 
supplementation with essential fatty acids (EFAs), specifically omega-3 and omega-6 LCPUFA, as an adjunct to 
conventional treatments in DES. Increased consumption of omega-3 fatty acids has been advocated in evidence-
based reviews and professional guidance on DES and associated conditions such as meibomian gland 
dysfunction [50-52].  Omega-3 and omega-6 EFA, which must be obtained from the diet, are precursors of 
eicosanoids that are locally-acting signalling molecules which regulate inflammation. Omega-3 LCPUFAs such 
as DHA and EPA are present in certain vegetable oils (e.g. flaxseed oil) and in oils from cold water fish and 
other marine animals. Omega-6 fatty LCPUFA e.g. arachidonic acid and linoleic acid are found in sunflower 
oils, evening primrose oil and animal fats. Omega-6 fatty acids e.g. linoleic (LA) can be metabolised into the 
pro-inflammatory mediators prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) via the arachidonic acid 
pathway or into less potent inflammatory mediators e.g. prostaglandin E1 (PGE1). Similarly, omega-3 LCPUFA 
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e.g. EPA, which act competitively for the enzymes cyclooxygenase and lipoxygenase, are metabolised into the 
less biologically active 3-series prostaglandins (Figure 2). The balance between intake of omega-3 and omega-6 
LCPUFA is likely to be a key factor in modulating the bodies’ inflammatory response and it can therefore be 
hypothesised that optimising the omega-3/omega-6 ratio may mitigate against the signs and symptoms 
associated with DES.  
Figure 2.  Metabolic pathways for dietary omega-3 and omega-6 EFA in eicosanoid synthesis.  
 
There is compelling data from observational studies on the value of increasing dietary intakes of omega-3 fats.  
For example, in a subset of participants in the Women’s Eye Study in the US (N=32,470) a higher intake of 
omega-3 was inversely associated with the incidence of DES [53]. By contrast, data from intervention studies on 
the benefit of supplementation with EFA are sparse. A recent systematic review [54] of RCTs investigating 
omega-3 LCPUFA for DES included data from 7 trials involving 720 participants. Although pooled data found 
a small but statistically significant increase in tear stability and quality, it is debatable whether these differences 
would be clinically meaningful.  Importantly no difference was found in the Ocular Surface Disease Index 
(which assessed the severity of symptoms associated with dry eye). In summary, although there is some 
evidence for the effectiveness of EFA supplementation in DES, more data is needed before supplements can be 
widely recommended. 
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Conclusions 
A large percentage of the general population is taking a diverse range of nutritional supplements to maintain or 
improve their overall health without any evidence-based justification. Supplementing the diet of well-nourished 
adults with mineral or vitamin supplements appear to have no clear benefit and might even be harmful. It is 
important that any advice given regarding supplements is informed by the best available research evidence. 
However, there is a dearth of high quality data from randomised trials on the effectiveness of these preparations 
for common age-related eye conditions such as AMD, cataract and DES. It should also be borne in mind that the 
use of high dose micronutrient supplements also has the potential for harm, for example several trials have 
reported higher rates of lung cancer in cigarette smokers who were taking nutritional supplements containing -
carotene and there is also the possibility of interactions of nutritional supplements with prescribed medications 
[55]. Currently there is insufficient evidence to recommend commercially available supplements for the 
prevention or treatment of cataract or DES. However, there is high quality evidence to support the use of an 
AREDS-formulation supplement containing antioxidants (-carotene, vitamin C and vitamin E) and zinc to slow 
progression in those patients at high risk of developing advanced AMD, including those with intermediate AMD 
in one or both eyes (AREDS category 3) or advanced AMD (AREDS category 4) in one eye, but not the other 
eye. Recent data from the AREDS2 trial provided further evidence that -carotene in the original AREDS 
formula could be replaced with lutein and zeaxanthin on the basis of improved safety without compromising 
efficacy. Given the current scale of the public health problem caused by age-related eye disease and with 
increasing longevity, reducing the risk of developing these diseases or slowing their progression through dietary 
modification should remain an important area for future research.  
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